Literature DB >> 15330508

Relevance of a combined HIV antigen/antibody assay to detect early HIV infections in a low prevalence population: case reports.

S Andersson1, B Asjö, P A Jenum, I Manner, G Njölstad, E Ragnhildstveit, K Skaug, B Söderquist, M von Sydow.   

Abstract

The AxSYM HIV Ag/Ab Combo assay (Abbott) has proven to possess excellent sensitivity on seroconversion samples. Since its introduction in Sweden and Norway approximately one year ago, eight cases of acute HIV infections were found earlier compared to assays detecting only antibodies either to screen or to confirm an HIV infection. Data of the presented cases indicate that the early detection of primary HIV infection is of benefit to the individual patient and may reduce further spread of the disease. The impact of HIV combo assays on screening and diagnosis in a low prevalence population is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330508

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  3 in total

1.  Combination assay detecting both human immunodeficiency virus (HIV) p24 antigen and anti-HIV antibodies opens a second diagnostic window.

Authors:  David Speers; Peter Phillips; John Dyer
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

2.  Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting.

Authors:  Mark W Pandori; John Hackett; Brian Louie; Ana Vallari; Teri Dowling; Sally Liska; Jeffrey D Klausner
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

3.  Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay.

Authors:  Susan H Eshleman; Leila Khaki; Oliver Laeyendecker; Estelle Piwowar-Manning; LeTanya Johnson-Lewis; Marla Husnik; Beryl Koblin; Thomas Coates; Margaret Chesney; Ana Vallari; Sushil G Devare; John Hackett
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.